Literature DB >> 17526744

Heptose I glycan substitutions on Neisseria gonorrhoeae lipooligosaccharide influence C4b-binding protein binding and serum resistance.

Sanjay Ram1, Jutamas Ngampasutadol, Andrew D Cox, Anna M Blom, Lisa A Lewis, Frank St Michael, Jacek Stupak, Sunita Gulati, Peter A Rice.   

Abstract

Lipooligosaccharide (LOS) heptose (Hep) glycan substitutions influence gonococcal serum resistance. Several gonococcal strains bind the classical complement pathway inhibitor, C4b-binding protein (C4BP), via their porin (Por) molecule to escape complement-dependent killing by normal human serum (NHS). We show that the proximal glucose (Glc) on HepI is required for C4BP binding to Por1B-bearing gonococcal strains MS11 and 1291 but not to FA19 (Por1A). The presence of only the proximal Glc on HepI (lgtE mutant) permitted maximal C4BP binding to MS11 but not to 1291. Replacing 1291 lgtE Por with MS11 Por increased C4BP binding to levels that paralleled MS11 lgtE, suggesting that replacement of the Por1B molecule dictated the effects of HepI glycans on C4BP binding. The remainder of the strain background did not affect C4BP binding; replacing the Por of strain F62 with MS11 Por (F62 PorMS11) and truncating HepI mirrored the findings in the MS11 background. C4BP binding correlated with resistance to killing by NHS in most instances. F62 PorMS11 and its lgtE mutant were sensitive to NHS despite binding C4BP, secondary to kinetically overwhelming classical pathway activation and possibly increased alternative pathway activation (measured by factor Bb binding) by the F62 background. FA19 lgtF (HepI unsubstituted) resisted killing by only 10% NHS, not 50% NHS, despite binding levels of C4BP similar to those of FA19 and FA19 lgtE (both resistant to 50% serum), suggesting a role for the proximal Glc in serum resistance independently of C4BP binding. This study provides mechanistic insights into how HepI LOS substitutions affect the serum resistance of N. gonorrhoeae.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17526744      PMCID: PMC1952009          DOI: 10.1128/IAI.01109-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  50 in total

1.  A novel interaction of outer membrane protein A with C4b binding protein mediates serum resistance of Escherichia coli K1.

Authors:  Nemani V Prasadarao; Anna M Blom; Bruno O Villoutreix; Linette C Linsangan
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

2.  Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.

Authors:  I Gigli; T Fujita; V Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

3.  Phase variable changes in genes lgtA and lgtC within the lgtABCDE operon of Neisseria gonorrhoeae can modulate gonococcal susceptibility to normal human serum.

Authors:  William M Shafer; Anup Datta; V S Kumar Kolli; M Mahbubur Rahman; Jacqueline T Balthazar; Larry E Martin; Wendy L Veal; David S Stephens; Russell Carlson
Journal:  J Endotoxin Res       Date:  2002

4.  Structural analysis of the lipopolysaccharide from the nontypable Haemophilus influenzae strain SB 33.

Authors:  A D Cox; H Masoud; P Thibault; J R Brisson; M van der Zwan; M B Perry; J C Richards
Journal:  Eur J Biochem       Date:  2001-10

5.  Immortalization of human urethral epithelial cells: a model for the study of the pathogenesis of and the inflammatory cytokine response to Neisseria gonorrhoeae infection.

Authors:  Hillery A Harvey; Deborah M B Post; Michael A Apicella
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

6.  Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificity.

Authors:  Sanjay Ram; Andrew D Cox; J Claire Wright; Ulrich Vogel; Silke Getzlaff; Ryan Boden; Jianjun Li; Joyce S Plested; Seppo Meri; Sunita Gulati; Daniel C Stein; James C Richards; E Richard Moxon; Peter A Rice
Journal:  J Biol Chem       Date:  2003-10-02       Impact factor: 5.157

7.  Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins.

Authors:  R D Schreiber; D C Morrison; E R Podack; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1979-04-01       Impact factor: 14.307

8.  Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae.

Authors:  S Ram; M Cullinane; A M Blom; S Gulati; D P McQuillen; B G Monks; C O'Connell; R Boden; C Elkins; M K Pangburn; B Dahlbäck; P A Rice
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

9.  Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator.

Authors:  T Fujita; I Gigli; V Nussenzweig
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

10.  The role of C4-binding protein and beta 1H in proteolysis of C4b and C3b.

Authors:  T Fujita; V Nussenzweig
Journal:  J Exp Med       Date:  1979-08-01       Impact factor: 14.307

View more
  15 in total

1.  An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae.

Authors:  Sarika Agarwal; Viviana P Ferreira; Claudio Cortes; Michael K Pangburn; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

2.  Phenotypic and genotypic analyses of Neisseria gonorrhoeae isolates that express frequently recovered PorB PIA variable region types suggest that certain P1a porin sequences confer a selective advantage for urogenital tract infection.

Authors:  Lotisha E Garvin; Margaret C Bash; Christine Keys; Douglas M Warner; Sanjay Ram; William M Shafer; Ann E Jerse
Journal:  Infect Immun       Date:  2008-06-09       Impact factor: 3.441

3.  Structure-function studies of the Neisseria gonorrhoeae major outer membrane porin.

Authors:  Adrienne Chen; H Steven Seifert
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

4.  Properdin is critical for antibody-dependent bactericidal activity against Neisseria gonorrhoeae that recruit C4b-binding protein.

Authors:  Sunita Gulati; Sarika Agarwal; Shreekant Vasudhev; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2012-02-24       Impact factor: 5.422

5.  Polyamines can increase resistance of Neisseria gonorrhoeae to mediators of the innate human host defense.

Authors:  Maira Goytia; William M Shafer
Journal:  Infect Immun       Date:  2010-05-03       Impact factor: 3.441

6.  Phosphoethanolamine residues on the lipid A moiety of Neisseria gonorrhoeae lipooligosaccharide modulate binding of complement inhibitors and resistance to complement killing.

Authors:  Lisa A Lewis; William M Shafer; Tathagat Dutta Ray; Sanjay Ram; Peter A Rice
Journal:  Infect Immun       Date:  2012-10-15       Impact factor: 3.441

7.  Phase-Variable Heptose I Glycan Extensions Modulate Efficacy of 2C7 Vaccine Antibody Directed against Neisseria gonorrhoeae Lipooligosaccharide.

Authors:  Srinjoy Chakraborti; Lisa A Lewis; Andrew D Cox; Frank St Michael; Jianjun Li; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2016-05-02       Impact factor: 5.422

8.  The periplasmic disulfide oxidoreductase DsbA contributes to Haemophilus influenzae pathogenesis.

Authors:  Charles V Rosadini; Sandy M S Wong; Brian J Akerley
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

9.  Outer membrane protein P5 is required for resistance of nontypeable Haemophilus influenzae to both the classical and alternative complement pathways.

Authors:  Charles V Rosadini; Sanjay Ram; Brian J Akerley
Journal:  Infect Immun       Date:  2013-11-25       Impact factor: 3.441

10.  Phosphoethanolamine substitution of lipid A and resistance of Neisseria gonorrhoeae to cationic antimicrobial peptides and complement-mediated killing by normal human serum.

Authors:  Lisa A Lewis; Biswa Choudhury; Jacqueline T Balthazar; Larry E Martin; Sanjay Ram; Peter A Rice; David S Stephens; Russell Carlson; William M Shafer
Journal:  Infect Immun       Date:  2008-12-29       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.